about
Tissue- and Serum-Associated Biomarkers of Hepatocellular CarcinomaProteoglycans in liver cancerEchographic imaging of tumoral cells through novel nanosystems for image diagnosis.Advances in liver cancer antibody therapies: a focus on glypican-3 and mesothelinCan serum glypican-3 be a biomarker for effective diagnosis of hepatocellular carcinoma? A meta-analysis of the literatureGPC-3 in hepatocellular carcinoma: current perspectivesGene expression profiling of liver cancer stem cells by RNA-sequencingPrognostic and clinicopathological significance of glypican-3 overexpression in hepatocellular carcinoma: a meta-analysisCan glypican-3 be a disease-specific biomarker?Construction of an immunotoxin, HN3-mPE24, targeting glypican-3 for liver cancer therapyInactivation of Wnt signaling by a human antibody that recognizes the heparan sulfate chains of glypican-3 for liver cancer therapy.Glypican-3-targeted 89Zr PET imaging of hepatocellular carcinoma.GPC3 reduces cell proliferation in renal carcinoma cell linesHeparan sulfate proteoglycans and human breast cancer epithelial cell tumorigenicity.Japanese phase I study of GC33, a humanized antibody against glypican-3 for advanced hepatocellular carcinoma.Immunotoxin targeting glypican-3 regresses liver cancer via dual inhibition of Wnt signalling and protein synthesis.Photoimmunotherapy of hepatocellular carcinoma-targeting Glypican-3 combined with nanosized albumin-bound paclitaxel.CK19 and Glypican 3 Expression Profiling in the Prognostic Indication for Patients with HCC after Surgical Resection.Aptamers against Cells Overexpressing Glypican 3 from Expanded Genetic Systems Combined with Cell Engineering and Laboratory EvolutionHigh-affinity monoclonal antibodies to cell surface tumor antigen glypican-3 generated through a combination of peptide immunization and flow cytometry screeningClinical correlation of calpain-1 and glypican-3 expression with gallbladder carcinoma.Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma.Epitope mapping by a Wnt-blocking antibody: evidence of the Wnt binding domain in heparan sulfate.Heparan sulfate proteoglycans containing a glypican 5 core and 2-O-sulfo-iduronic acid function as Sonic Hedgehog co-receptors to promote proliferationHumanization of high-affinity antibodies targeting glypican-3 in hepatocellular carcinomaGlypican-3 antibodies: a new therapeutic target for liver cancer.Therapeutic potential of targeting glypican-3 in hepatocellular carcinoma.A spoonful of sugar makes the melanoma go: the role of heparan sulfate proteoglycans in melanoma metastasis.GPI transamidase and GPI anchored proteins: oncogenes and biomarkers for cancer.Targeting of hepatocellular carcinoma with glypican-3-targeting peptide ligand.Expression profile of altered long non-coding RNAs in patients with HBV-associated hepatocellular carcinoma.A novel miR-219-SMC4-JAK2/Stat3 regulatory pathway in human hepatocellular carcinomaImmunotherapy of hepatocellular carcinoma using chimeric antigen receptors and bispecific antibodies.MiR-219-5p inhibits hepatocellular carcinoma cell proliferation by targeting glypican-3.A targeted functional RNA interference screen uncovers glypican 5 as an entry factor for hepatitis B and D viruses.Immunotherapy of hepatocellular carcinoma: Unique challenges and clinical opportunities.Regulation of TGFβ superfamily signaling by two separable domains of glypican LON-2 in C. elegans.Retinoic acid induced 16 enhances tumorigenesis and serves as a novel tumor marker for hepatocellular carcinoma.Quantification of glypican 3, β-catenin and claudin-1 protein expression in hepatoblastoma and paediatric hepatocellular carcinoma by colour deconvolution.Codelivery of sorafenib and GPC3 siRNA with PEI-modified liposomes for hepatoma therapy.
P2860
Q26743361-86466568-110F-4E59-B651-3C827A317017Q26772304-98426F73-1C92-4472-BCE0-5B03A8572D65Q27012856-97B8DCFD-2774-49CD-BA78-E398632E9E9BQ27015134-1AFF0282-FDC6-454E-AA27-05E74159AC28Q27023427-14F77A22-7A24-4E8D-9441-DFC5F0350A32Q28066774-9FF10B1F-5B16-4AE2-A7DF-823CA5185237Q28483663-1133CD96-42CA-47C6-AA6B-CE09E72C21D2Q33661257-516BA706-88CC-40DB-99C4-545E3C0326C2Q33694272-1AFBC06A-B601-4915-B1E4-12552B66AB51Q33779122-1D48B25E-FE41-48FC-8A52-E8D4107DA4D9Q33850265-E076612C-7723-4C7F-BFEB-2D473E3983B0Q33974776-BBD8BE56-12D9-4BCF-A03E-7CAA0C4C2016Q34169151-52546DE3-FA17-4247-AFE8-539C206F256CQ34475894-390FA6D3-26C9-4BD4-B1D4-586535B2BC67Q35051445-F66FB7C1-C93C-42D5-8F7F-64035556505AQ35170403-9714D81D-6A38-4CCA-9492-F6A4BB343269Q35570817-0992D1B6-AA5A-4851-8D32-00434921D6FAQ35957183-A5B48FF0-FE99-400B-BB8B-C085D05AFADDQ36124808-8B5CE1DB-56DB-4843-9AD9-5E652271E46BQ36402695-2F6ACD46-9A5B-4C34-92A4-FB9EB170D776Q36524756-FE6B4EAF-63DD-40EC-9376-5473D7E7668CQ36712597-C393DE8D-CB14-41C7-ACEC-1750A409BCC4Q36906823-2614F475-F2C3-425B-BDF8-3F55566A2F06Q37151121-EB02DB59-6414-4A49-BE54-1F1D598FAA4FQ37282388-520FC8F3-C150-452F-A22A-42FD45996ED7Q37625736-4240A4CE-9090-4EDA-ACB7-DBB9810B3B20Q37873514-39639866-17CC-43A6-BC48-11D50139BC80Q37943014-4D6EEAC9-03AD-485C-9056-A2EEA3785193Q38131553-691A4722-6CF0-4843-A220-2273216CCB57Q38331349-132DDFC0-5F87-4A43-909A-4C139F006801Q38492203-78D86A05-AB1C-4C1F-A416-BB141391190AQ38979570-D15E717A-4034-4AEF-A74C-BB54C6C37722Q39253341-E0C916C0-F900-4B30-9587-770641D30400Q39373710-CE1A2963-3A89-43A4-80F2-CEB48AFAFBACQ41082130-41DA2585-0C1D-4431-896A-4960F6D3BC15Q42024872-F59DFC17-AEF2-4B0A-8530-CEC6F7277F0CQ42770522-47241D69-50E5-452F-BD5D-6622E41678DCQ45881792-05A16BE3-EFEA-4228-B0C2-24E82C46DF06Q46405678-89EA67BE-D04B-4FFD-AD29-5E1CE25A23C5Q47378147-022BEE3C-D344-47B6-8ED5-AF58C86E70D7
P2860
description
2010 nî lūn-bûn
@nan
2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Glypican-3: a new target for cancer immunotherapy.
@ast
Glypican-3: a new target for cancer immunotherapy.
@en
Glypican-3: a new target for cancer immunotherapy.
@nl
type
label
Glypican-3: a new target for cancer immunotherapy.
@ast
Glypican-3: a new target for cancer immunotherapy.
@en
Glypican-3: a new target for cancer immunotherapy.
@nl
prefLabel
Glypican-3: a new target for cancer immunotherapy.
@ast
Glypican-3: a new target for cancer immunotherapy.
@en
Glypican-3: a new target for cancer immunotherapy.
@nl
P2860
P1476
Glypican-3: a new target for cancer immunotherapy.
@en
P2093
Heungnam Kim
Mitchell Ho
P2860
P304
P356
10.1016/J.EJCA.2010.10.024
P577
2010-11-26T00:00:00Z